Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications

Journal of Medicinal Chemistry

Volumn 60, Issue 6, 2017, Pages 2470-2484

  Galambos, János ^a   Bielik, Attila ^a   Krasavin, Mikhail ^b   Orgován, Zoltán ^c   Domány, György ^a   Nógrádi, Katalin ^a   Wágner, Gábor ^a   Balogh, György T ^a   Béni, Zoltán ^a   Kóti, János ^a   Szakács, Zoltán ^a   Bobok, Amrita ^a   Kolok, Sándor ^a   Mikó Bakk, Mónika L ^a   Vastag, Mónika ^a   Sághy, Katalin ^a   Laszy, Judit ^a   Halász, Attila Sándor ^a   Balázs, Ottilia ^a   Gál, Krisztina ^a   Greiner, István ^a   Szombathelyi, Zsolt ^a   Keserű, György M ^c   more..

^a GEDEON RICHTER LTD   (Hungary)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 CHLORO 4 FLUOROPHENYL)SULFONYL] 4 (4 CHLOROOPHENYL) 7 FLUOROQUINOLINE; 3 [(3,5 DICHLOROPHENYL)SULFONYL] 7 FLUORO 4 (3 FLUOROPHENYL)QUINOLINE; 3 [(3,5 DICHLOROPHENYL)SULFONYL] 7 FLUORO 4 (4 FLUOROPHENYL)QUINOLINE; 3 [(3,5 DIFLUOROPHENYL)SULFONYL] 7 FLUORO 4 (3 FLUOROPHENYL)QUINOLINE; 3 [(3,5 DIFLUOROPHENYL)SULFONYL] 7 FLUORO 4 (4 FLUOROPHENYL)QUINOLINE; 3 [(3,5 DIFLUOROPHENYL)SULFONYL] 8 FLUORO 4 (4 FLUOROPHENYL)QUINOLINE; 3 [[4 [(4 CHLOROPHENYL) 7 FLUOROQUINOLIN 3YL]SULFONYL]BENZONITRILE; 3 [[7 FLUORO 4 (4 FLUOROPHENYL)QUINOLIN 3 YL]SULFONYL]BENZONITRILE; 4 (4 CHLOROPHENYL) 3 [(3,4 DICHLOROPHENYL)SULFONYL] 8 FLUOROQUINOLINE; 4 (4 CHLOROPHENYL) 3 [(3,4 DIFLUOROPHENYL)SULFONYL] 7 FLUOROQUINOLINE; 4 (4 CHLOROPHENYL) 3 [(3,5 DICHLOROPHENYL)SULFONYL] 7 FLUOROQUINOLINE; 4 (4 CHLOROPHENYL) 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE 6 CARBONITRILE; 4 (4 CHLOROPHENYL) 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE 7 CARBONITRILE; 4 (4 CHLOROPHENYL) 6 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 4 (4 CHLOROPHENYL) 7 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 4 (4 CHLOROPHENYL) 8 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 6 CHLORO 4 (4 CHLOROPHENYL) 7 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 6 CHLORO 4 (4 CHLOROPHENYL) 8 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 7 CHLORO 4 (4 CHLOROPHENYL) 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 7 CHLORO 4 (4 CHLOROPHENYL) 6 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 7 CHLORO 4 (4 CHLOROPHENYL) 8 FLUORO 3 [(4 FLUOROPHENYLSULFONYL)]QUINOLINE; 8 FLUORO 4 (4 FLUOROPHENYL) 3 [(3 FLUOROPHENYL)SULFONYL]QUINOLINE; AMINO ACID RECEPTOR AFFECTING AGENT; ANXIOLYTIC AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; DIAZEPAM; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG; BENZONITRILE; NITRILE; QUINOLINE DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC STABILITY; MORRIS WATER MAZE TEST; NONHUMAN; PHARMACOPHORE; RAT; SYSTEMATIC REVIEW; THERAPEUTIC INDEX; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; HALOGENATION; MACACA FASCICULARIS; MAZE TEST; METABOLISM; MOLECULAR DOCKING;

ALLOSTERIC REGULATION; ANIMALS; ANTI-ANXIETY AGENTS; DOGS; FEMALE; HALOGENATION; HUMANS; MACACA FASCICULARIS; MALE; MAZE LEARNING; MOLECULAR DOCKING SIMULATION; NITRILES; QUINOLINES; RATS; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 85016313276     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01858     Document Type: Article

References (35)

1. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function Science 1992, 258, 597-603 10.1126/science.1329206
2. Bailey, D. B.; Berry-Kravis, E.; Wheeler, A.; Raspa, M.; Merrien, F.; Ricart, J.; Koumaras, B.; Rosenkranz, G.; Tomlinson, M.; von Raison, F.; Apostol, G. Mavoglurant in adolescents with fragile X syndrome: analysis of clinical global impression-improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study J. Neurodev. Disord. 2016, 8, 1 10.1186/s11689-015-9134-5
3. Pecknold, J. C.; McClure, D. J.; Appeltauer, L.; Wrzesinski, L.; Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J. Clin. Psychopharmacol. 1982, 2, 129-133 10.1097/00004714-198204000-00010
4. Quiroz, J. A.; Tamburri, P.; Deptula, D.; Banken, L.; Beyer, U.; Fontoura, P.; Santarelli, L. The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study Eur. Neuropsychopharmacol. 2014, 24, S468 10.1016/S0924-977X(14)70748-5
5. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31 10.1016/j.tips.2008.10.006
6. Balschun, D.; Zuschratter, W.; Wetzel, W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory Neuroscience 2006, 142, 691-702 10.1016/j.neuroscience.2006.06.043
7. Stefani, M. R.; Moghaddam, B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade Eur. J. Pharmacol. 2010, 639, 26-32 10.1016/j.ejphar.2010.01.028
8. Lindsley, C. W.; Emmitte, K. A.; Hopkins, C. R.; Bridges, T. M.; Gregory, K. J.; Niswender, C. M.; Conn, P. J. Practical strategiess and conceptsc in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors Chem. Rev. 2016, 116, 6707-6741 10.1021/acs.chemrev.5b00656
9. Keywood, C.; Wakefield, M.; Tack, J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease Gut 2009, 58, 1192-1199 10.1136/gut.2008.162040
10. Jaeschke, G.; Kolczewski, S.; Spooren, W.; Vieira, E.; Bitter-Stoll, N.; Boissin, P.; Borroni, E.; Büttelmann, B.; Ceccarelli, S.; Clemann, N.; David, B.; Funk, C.; Guba, W.; Harrison, A.; Hartung, T.; Honer, M.; Huwyler, J.; Kuratli, M.; Niederhauser, U.; Pahler, A.; Peters, J.-U.; Petersen, A.; Prinssen, E.; Ricci, A.; Rueher, D.; Rueher, M.; Schneider, M.; Spurr, P.; Stoll, T.; Tannler, D.; Wichmann, J.; Porter, R. H.; Wettstein, J. G.; Lindemann, L. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases J. Med. Chem. 2015, 58, 1358-1371 10.1021/jm501642c
11. Vranesic, I.; Ofner, S.; Flor, P. J.; Bilbe, G.; Bouhelal, R.; Enz, A.; Desrayaud, S.; McAllister, K.; Kuhn, R.; Gasparini, F. AFQ056/ mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization Bioorg. Med. Chem. 2014, 22, 5790-5803 10.1016/j.bmc.2014.09.033
12. Tison, F.; Keywood, C.; Wakefield, M.; Durif, F.; Corvol, J.-C.; Eggert, K.; Lew, M.; Isaacson, S.; Bezard, E.; Poli, S.-M.; Goetz, C. G.; Trenkwalder, C.; Rascol, O. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson’s Disease Mov. Disord. 2016, 31, 1373-1380 10.1002/mds.26659
13. Raboisson, P.; Breitholtz-Emanuelsson, A.; Dahllöf, H.; Edwards, L.; Heaton, W. L.; Isaac, M.; Jarvie, K.; Kers, A.; Minidis, A. B.; Nordmark, A.; Sheehan, S. M.; Slassi, A.; Ström, P.; Terelius, Y.; Wensbo, D.; Wilson, J. M.; Xin, T.; McLeod, D. A. Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development Bioorg. Med. Chem. Lett. 2012, 22, 6974-6979 10.1016/j.bmcl.2012.08.100
14. Christopher, J. A.; Aves, S. J.; Bennett, K. A.; Doré, A. S.; Errey, J. C.; Jazayeri, A.; Marshall, F. H.; Okrasa, K.; Serrano-Vega, M. J.; Tehan, B. G.; Wiggin, G. R.; Congreve, M. Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile) J. Med. Chem. 2015, 58, 6653-6664 10.1021/acs.jmedchem.5b00892
15. Galambos, J.; Domány, G.; Nógrádi, K.; Wágner, G.; Keserű, G. M.; Bobok, A.; Kolok, S.; Mikó-Bakk, M. L.; Vastag, M.; Sághy, K.; Kóti, J.; Szakács, Z.; Béni, Z.; Gál, K.; Szombathelyi, Z.; Greiner, I. 4-Aryl-3-arylsulfonyl-quinolines as negative allosteric modulators of metabotropic GluR5 receptors: from HTS hit to development Bioorg. Med. Chem. Lett. 2016, 26, 1249-1252 10.1016/j.bmcl.2016.01.024
16. Nógrádi, K.; Wágner, G.; Domány, G.; Bobok, A.; Magdó, I.; Kiss, B.; Kolok, S.; Fónagy, K.; Gyertyán, I.; Háda, V.; Kóti, J.; Gál, K.; Farkas, S.; Keserű, G. M.; Greiner, I.; Szombathelyi, Z. Thieno[2,3-b]pyridines as negative allosteric modulators of metabotropic GluR5 receptors: hit-to-lead optimization Bioorg. Med. Chem. Lett. 2014, 24, 3845-3849 10.1016/j.bmcl.2014.06.057
17. Nógrádi, K.; Wágner, G.; Domány, G.; Bobok, A.; Magdó, I.; Kolok, S.; Mikó-Bakk, M. L.; Vastag, M.; Sághy, K.; Gyertyán, I.; Kóti, J.; Gál, K.; Farkas, S.; Keserű, G. M.; Greiner, I.; Szombathelyi, Z. Thieno[2,3-b]pyridines as negative allosteric modulators of metabotropic GluR5 receptors: lead optimization Bioorg. Med. Chem. Lett. 2015, 25, 1724-1729 10.1016/j.bmcl.2015.02.073
18. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulatorsm of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54 10.1038/nrd2760
19. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. “Molecular switches” on mGluR allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2410 10.1021/bi200129s
20. 5-Selective and CNS Penetrant Negative Allosteric Modulator (NAM) of a Muscarinic Acetylcholine Receptor: (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375) J. Med. Chem. 2013, 56, 9351-9355 10.1021/jm4013246
21. Kurata, H.; Gentry, P. R.; Kokubo, M.; Cho, H. P.; Bridges, T. M.; Niswender, C. M.; Byers, F. W.; Wood, M. R.; Daniels, J. S.; Conn, P. J.; Lindsley, C. W. Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges Bioorg. Med. Chem. Lett. 2015, 25, 690-694 10.1016/j.bmcl.2014.11.082
22. Rydberg, P.; Gloriam, D. E.; Olsen, L. The SmartCyp cytochrome P450 metabolism prediction server Bioinformatics 2010, 26, 2988-2989 10.1093/bioinformatics/btq584
23. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders Nat. Rev. Drug Discovery 2014, 13, 692-708 10.1038/nrd4308
24. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M. A.; Johnson, E. C.; Hess, S. D.; Rao, S. P.; Sacaan, A. I.; Santori, E. M.; Velicelebi, G.; Kuhn, R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist Neuropharmacology 1999, 38, 1493-1503 10.1016/S0028-3908(99)00082-9
25. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 1995, 25, 366-428 10.1016/S1043-9471(05)80049-7
26. Mason, J. S.; Bortolato, A.; Weiss, D. R.; Deflorian, F.; Tehan, B.; Marshall, F. High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks In Silico Pharmacol. 2013, 1, 23 10.1186/2193-9616-1-23
27. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry ChemMedChem 2008, 3, 1179-1180 10.1002/cmdc.200800132
28. Harpsøe, K.; Isberg, V.; Tehan, B. G.; Weiss, D.; Arsova, A.; Marshall, F. H.; Bräuner-Osborne, H.; Gloriam, D. E. Selective negative allosteric modulation of metabotropic glutamate receptors - A structural perspective of ligands and mutants Sci. Rep. 2015, 5, 13869 10.1038/srep13869
29. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5 Bioorg. Med. Chem. Lett. 2002, 12, 407-409 10.1016/S0960-894X(01)00767-3
30. Lavreysen, H.; Janssen, C.; Bischoff, F.; Langlois, X.; Leysen, J. E.; Lesage, A. S. 3HR214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists Mol. Pharm. 2003, 63, 1082-1093 10.1124/mol.63.5.1082
31. Pouton, C. W. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 2006, 29, 278-287 10.1016/j.ejps.2006.04.016
32. Kuhne, S.; Kooistra, A. J.; Bosma, R.; Bortolato, A.; Wijtmans, M.; Vischer, H. F.; Mason, J. S.; de Graaf, C.; de Esch, I. J.; Leurs, R. Identification of ligand binding hot spots of the histamine H1 receptor following structure-based fragment optimization J. Med. Chem. 2016, 59, 9047-9061 10.1021/acs.jmedchem.6b00981
33. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857 10.1021/jm00145a002
34. Rane, A.; Wilkinson, G. R.; Shand, D. G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance J. Pharmacol. Exp. Ther. 1977, 200, 420-424
35. Vogel, J. R.; Beer, B.; Clody, D. E. A simple and reliable conflict procedure for testing anti-anxiety agents Psychopharmacologia 1971, 21, 1-7 10.1007/BF00403989